| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Caris Life Sciences, Inc.$15.73
+0.17 (+1.09%)
0Pipeline Score Diagnostics · Pre-Clinical
Market Cap
4.40 B
EPS
-1.47
P/E Ratio
-
Value Trade
43.89 M
SEC Financials
Q1 2026Dilution Risk
Revenue
216.17 M
R&D Expenses
31.32 M
Operating CF
32.88 M
Total Assets
1.16 B
Total Liabilities
568.90 M
Equity
593.49 M
D/E Ratio
12,345
1.97 %
Week
-26.48 %
1 Month
-24.66 %
3 Month
-34.94 %
6 Month
-42.41 %
5 Year
-42.41 %
All Time
Cash Data
Cash Position
822.22 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
3.19 M
52 Week Range
14.19 - 42.50
% held by Insiders
56.72 %
% held by Institutions
48.3 %
Enterprise Value
4.00 B
Total Shares
282.93 M
Short %
11.59 %
Float Shares
94.50 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Caris Life Sciences, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
TBD
▲Product LaunchPost-Market
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
0
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 0%
Micro Cap (rank 914 of 913)
Percentile RankClinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
pembrolizumab | — | — | 2026-05-11 | In a study of 3,981 'TMB reliant' patients treated with pembrolizumab, those with WES TMB-High and panel TMB-Low had a median overall survival of approximately five months longer compared to those with WES TMB-Low and panel TMB-High (p < 0.05). Read More | Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels Read More | |
pembrolizumab | — | — | 2026-05-11 | In a study of 3,981 'TMB reliant' patients treated with pembrolizumab, those with WES TMB-High and panel TMB-Low had a median overall survival of approximately five months longer compared to those with WES TMB-Low and panel TMB-High (p < 0.05). Read More | Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels Read More | |
pembrolizumab | — | — | 2026-05-11 | In a study of 3,981 'TMB reliant' patients treated with pembrolizumab, those with WES TMB-High and panel TMB-Low had a median overall survival of approximately five months longer compared to those with WES TMB-Low and panel TMB-High (p < 0.05). Read More | Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CAI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CAI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CAI▼ -5.6%on this news
Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Caris Life Sciences has announced that it will report its financial results for the second quarter of 2026 on August 5, 2026. The company will host a live webcast to discuss these results at 3:30 p.m. CT. Caris is known for its innovative solutions in precision medicine, utilizing advanced technologies for healthcare transformation.
Read more →CAICaris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing
Caris Life Sciences has announced the launch of in-house PTEN immunohistochemistry (IHC) testing following FDA approval of a biomarker-guided therapy for PTEN-deficient metastatic prostate cancer. This advancement allows oncologists to better identify eligible patients for personalized treatment, marking a significant step forward in precision oncology. The new testing capability is expected to enhance treatment decisions and improve patient outcomes.
Read more →CAIMasters in Thoracic Oncology Summit – MaTOS LATAM Panama
The article announces the 'Masters in Thoracic Oncology Summit – MaTOS LATAM Panama' event. It provides minimal details about the event itself, focusing primarily on its title and location. Further information regarding the agenda or speakers is not included.
Read more →CAI▲ +5.2%on this newsshared move
Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test
Caris Life Sciences has launched Caris Detect, a multi-cancer early detection blood test that utilizes ultra-deep Whole Genome and Whole Transcriptome sequencing combined with AI. This innovative test aims to identify cancer signals at earlier stages, improving treatment outcomes. The launch is supported by data from the Caris Detect ACHIEVE 1 study, demonstrating its effectiveness across multiple cancer types.
Read more →CAICaris Life Sciences Announces Dual Listing on NYSE Texas
Caris Life Sciences announced a dual listing of its common stock on NYSE Texas, effective June 17, 2026. This move aims to enhance its visibility in the public markets while maintaining its primary listing on NASDAQ. The company's CEO highlighted the significance of this milestone in reflecting their growth and commitment to innovation in precision medicine.
Read more →CAICaris Life Sciences Announces Share Repurchase Program
Caris Life Sciences has announced a share repurchase program authorized by its Board of Directors, allowing the company to buy back up to $100 million of its common stock. The repurchases can occur through various methods, including open market purchases, and will depend on market conditions and the company's financial health. The program offers flexibility but does not obligate the company to repurchase a specific number of shares.
Read more →CAI▼ -6.3%on this newsshared move
Japan Society of Clinical Oncology (JSCO) – Annual Meeting
The Japan Society of Clinical Oncology (JSCO) is hosting its Annual Meeting. This event serves as a platform for discussing advancements in clinical oncology and fostering collaboration among professionals in the field. Details regarding the agenda and speakers have not been provided in the article.
Read more →CAICaris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing
Caris Life Sciences has launched the "Behind the Diagnosis" campaign, showcasing patient stories transformed by its genomic testing. The inaugural story features Erika Rios, whose misdiagnosis of stage 4 metastatic breast cancer was corrected to Hodgkin lymphoma through Caris' AI-powered GPSai model. This correction led to a more effective treatment plan, emphasizing the importance of accurate molecular profiling in oncology.
Read more →CAICaris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek
Caris Life Sciences has published a study showcasing the Caris Lookback Program, which identifies patients eligible for newly approved targeted therapies based on their previous molecular profiles. The program continuously monitors FDA approvals and therapeutic guidelines, allowing for proactive notifications to oncologists. This approach enhances the clinical utility of comprehensive testing and supports ongoing advancements in precision oncology.
Read more →CAICaris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels
Caris Life Sciences published a study demonstrating that Whole Exome Sequencing (WES) offers a more accurate measurement of tumor mutational burden (TMB) than targeted gene panels. The research indicates that WES can lead to better patient outcomes by correctly identifying those eligible for pembrolizumab immunotherapy. The findings emphasize the necessity of using WES for precise therapy selection in cancer treatment.
Read more →CAI▼ -18.6%on this newsshared move
Caris Life Sciences Reports First Quarter 2026 Financial Results
Caris Life Sciences reported a strong financial performance for Q1 2026, with total revenue reaching $216.2 million, a 79% increase from the previous year. The growth was primarily driven by an 85% surge in molecular profiling services. The company also noted a significant reduction in net loss and reaffirmed its revenue guidance for the full year, projecting growth between 23% and 26%. CEO David Dean Halbert highlighted the demand for their platform and the positive data from their Achieve 1 study.
Read more →CAI▼ -18.6%on this newsshared move
Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization
Caris Life Sciences has submitted an application to the New York State Department of Health for authorization to perform its blood-based molecular profiling test, Caris Assure. This test analyzes genetic information to support comprehensive biomarker analysis. The application initiates a formal review process, and until authorized, the test cannot be used on New York specimens.
Read more →CAICaris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis
Caris Life Sciences has launched Caris MI Clarity, an AI-powered test that predicts both early and late distant recurrence risk for postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. This innovative test provides results within three business days, significantly faster than traditional methods. It aims to enhance treatment personalization by integrating pathology and clinical data, addressing the evolving nature of recurrence risk over time.
Read more →CAICaris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies
Caris Life Sciences has announced that its Caris ChromoSeq assay has received MolDX approval, which is expected to improve access to comprehensive genomic profiling for myeloid malignancies. This approval signifies that the assay meets clinical validity and utility standards, allowing for better diagnosis and treatment decisions. Caris ChromoSeq is noted for its ultra-deep whole genome sequencing capabilities, providing detailed insights into complex cancers.
Read more →CAICaris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients
Caris Life Sciences has published a study validating its AI-derived predictive signature for assessing the benefit of temozolomide (TMZ) in glioblastoma patients. The study, involving over 5,800 patients, demonstrates the model's high concordance with traditional MGMT testing methods and its potential to improve treatment outcomes. This advancement aims to enhance precision oncology by providing actionable insights for clinicians.
Read more →CAICaris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference
Caris Life Sciences announced its participation in two upcoming healthcare conferences: the BofA Securities 2026 Health Care Conference in Las Vegas and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami. The presentations will showcase Caris's advancements in precision medicine and AI technologies. Live webcasts of the presentations will be available on their Investor Relations website.
Read more →CAICaris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026
Caris Life Sciences has announced that it will report its first quarter 2026 financial results on May 7, 2026. The company will host a live webcast at 3:30 p.m. CT to discuss these results. Caris is recognized for its advancements in AI and precision medicine, aiming to transform healthcare through innovative solutions.
Read more →CAICaris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center
Caris Life Sciences has announced that the UCSF Helen Diller Family Comprehensive Cancer Center has joined its Precision Oncology Alliance. This collaboration aims to enhance cancer research and patient care through advanced molecular insights and precision medicine. The partnership is expected to deepen research efforts and improve clinical outcomes for cancer patients.
Read more →CAICaris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients
Caris Life Sciences has launched its Right-In-Time (RIT) clinical trial solution to improve access to precision oncology trials for underserved cancer patients. This initiative aims to bridge the gap in clinical trial availability, particularly in community oncology practices, by deploying trials directly to over 600 locations nationwide. The RIT solution integrates molecular profiling with automated trial matching, significantly reducing the time from diagnosis to trial enrollment.
Read more →CAICaris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients
Caris Life Sciences has launched an AI-driven molecular insight tool aimed at optimizing treatment decisions for non-small cell lung cancer (NSCLC) patients. This tool helps identify which patients may benefit from chemotherapy, potentially reducing unnecessary exposure to harmful treatments. The innovation leverages advanced sequencing technologies and real-world data to enhance precision oncology.
Read more →CAICaris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies
Caris Life Sciences has launched Caris ChromoSeq, a groundbreaking assay for whole genome and transcriptome sequencing aimed at myeloid malignancies. This innovative test is designed to streamline the diagnostic process, providing comprehensive genomic insights for conditions like acute myeloid leukemia and myelodysplastic syndromes. With a rapid turnaround time, it enhances clinical decision-making for healthcare providers.
Read more →CAI▲ +7%on this newsshared move
Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect
Caris Life Sciences has finalized the results of its Achieve 1 Study, demonstrating the superior sensitivity and specificity of its Caris Detect multi-cancer early detection test. The study involved 3,014 high-risk patients and confirmed the effectiveness of Whole Genome Sequencing in identifying early-stage cancers. The company plans to enhance the test further by incorporating additional molecular profiling techniques.
Read more →CAICaris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer
Caris Life Sciences has introduced new AI Insights that predict the risk of brain metastases in breast and lung cancer patients. These insights are part of the Caris Molecular Tumor Board Report, enhancing clinical decision-making. The proprietary algorithms are based on extensive patient data, allowing for personalized treatment strategies. This advancement aims to shift cancer care from passive monitoring to proactive management.
Read more →CAICaris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026
Caris Life Sciences will present six oncology studies at the 2026 AACR Annual Meeting, focusing on various cancers. These studies utilize Caris' multimodal database, combining genomic profiling with real-world clinical data. The research aims to uncover insights that can inform treatment decisions and enhance precision oncology. The event will take place in San Diego from April 17-22, 2026.
Read more →CAICaris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month
Caris Life Sciences emphasizes the critical role of DPYD testing in colorectal cancer treatment during Colorectal Cancer Awareness Month. The company advocates for genetic testing to mitigate risks associated with fluoropyrimidine-based therapies. Despite growing awareness, DPYD testing remains inconsistent in clinical practice, prompting Caris to integrate this testing into its molecular profiling assays. This initiative aims to enhance patient safety and treatment outcomes.
Read more →CAICaris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients
Caris Life Sciences has published a study in JAMA Network Open showcasing the effectiveness of its GPSai algorithm in accurately diagnosing lung cancer. The study revealed that GPSai identified misdiagnoses in 123 out of 3,958 cases, leading to improved treatment recommendations for 88 patients. This advancement highlights the importance of AI in enhancing precision medicine and patient care.
Read more →CAICaris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer
Caris Life Sciences has launched a new AI signature to predict early platinum resistance in high-grade serous ovarian cancer. This innovation aims to provide clinicians with critical insights into patient responses to first-line platinum-based chemotherapy. The tool integrates data from various sources to enhance treatment planning and improve patient outcomes in precision oncology.
Read more →CAICaris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer
Caris Life Sciences has launched a proprietary Caris AI Insights signature aimed at guiding first-line therapy selection and treatment de-escalation for pancreatic cancer. This innovative tool utilizes Whole Exome Sequencing and Whole Transcriptome Sequencing to provide actionable insights for clinicians. The signature is designed to enhance personalized treatment decisions for patients with pancreatic ductal adenocarcinoma, addressing the challenges of limited biomarker guidance in therapy selection.
Read more →CAI/C O R R E C T I O N -- Caris Life Sciences/
Caris Life Sciences has announced an interim readout of its Achieve 1 study, highlighting the effectiveness of Whole Genome Sequencing in early cancer detection. The study aims to support the upcoming launch of Caris Detect, a multi-cancer early detection test. Results indicate a significant milestone in identifying cancers at treatable stages, leveraging advanced AI and molecular insights.
Read more →CAI▲ +5.1%on this newsshared move
Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Full year revenue growth of 97% driven by strong performance in molecular profiling services Expects full year 202
Caris Life Sciences reported significant financial results for the fourth quarter and full year of 2025, with total revenue increasing by 97% to $812 million. The company's growth was primarily driven by enhanced performance in molecular profiling services, which saw a 199% increase in revenue for Q4 alone. The firm anticipates 2026 revenue to fall between $1.0 billion and $1.02 billion with continued growth in clinical therapy selection volumes. However, a net loss of $68.1 million was recorded, causing a need for careful management of increasing operating expenses moving forward.
Read more →CAICaris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients’ Oral Chemotherapy Drug
Caris Life Sciences has launched a new breast cancer signature in its Molecular Tumor Board Report, aimed at predicting responses to the oral chemotherapy drug capecitabine for HER2-negative breast cancer patients. This signature leverages extensive clinico-genomic data to guide personalized treatment strategies. The report is available upon request with the MI Cancer Seek order, enhancing the company's precision medicine offerings.
Read more →CAI▼ -9.7%on this newsshared move
Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference
Caris Life Sciences will participate in the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, in Boston, Massachusetts. The company is known for its patient-centric approach and innovative solutions in precision medicine. Caris utilizes advanced AI and molecular profiling to enhance healthcare delivery.
Read more →CAICaris Life Sciences’ Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan
Caris Life Sciences published a study in Nature's npj Breast Cancer, revealing mechanisms of resistance to trastuzumab deruxtecan in metastatic breast cancer. The research utilized extensive real-world data and multiomic profiling to identify molecular features linked to treatment outcomes. Key findings suggest that higher ERBB2 expression correlates with better survival, while ABCC1 is associated with poorer outcomes, indicating a need for refined patient stratification.
Read more →CAICaris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results
Caris Life Sciences reported preliminary financial results for Q4 and full year 2025, highlighting a remarkable 94% revenue growth driven by molecular profiling services. The company, which became public in 2025, aims to expand clinical adoption and advance its pipeline. However, the results are preliminary and unaudited, indicating potential changes before final reporting.
Read more →CAICaris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Caris Life Sciences will present at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco. The presentation includes a Q&A session on January 12 at 1:30 PM PT. Caris is known for its advancements in precision medicine and AI-driven healthcare solutions.
Read more →CAIThe Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute
Caris Life Sciences announced the inclusion of Providence Swedish Cancer Institute in its Precision Oncology Alliance. This partnership aims to enhance precision oncology through collaborative research and innovative cancer treatments. With this addition, the Caris POA now comprises 99 institutions, leveraging advanced molecular profiling and AI to improve patient outcomes.
Read more →CAI▼ -6.3%on this news· ran to -21% by day 1
Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 113% driven by strong performance in molecular profiling services Raises 2025 revenue guidance to $72
Caris Life Sciences reported robust financial results for the third quarter of 2025, showcasing a revenue increase of 113.4% to $216.8 million compared to the same quarter in the prior year. The company raised its revenue guidance for the full year 2025 to a range of $720 to $730 million, reflecting strong growth prospects. Notably, Caris achieved a positive net income of $24.3 million, a contrast to the net loss recorded in the previous year. Their gross margin improved to 68%, underscoring the operational strength of their molecular profiling services.
Read more →CAI▲ +7.4%on this news· ran to +21% by day 3
Caris Life Sciences Reports Second Quarter 2025 Financial Results
Caris Life Sciences reported robust second quarter financial results for 2025, with total revenue reaching $181.4 million, an 81.3% increase from the previous year. Key highlights included a significant surge in molecular profiling revenue and a positive Adjusted EBITDA of $16.7 million. However, the company reported a net loss of $71.8 million, influenced by one-time expenses related to its IPO. Moving forward, Caris projects a full-year revenue growth of 64% to 66% for 2025.
Read more →Competitive Position
How CAI ranks across every disease it competes inCompetitive Position is a premium feature
See how CAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial